Abstract infertility and premature menopause are possible side effects of chemotherapy in young women with breast cancer and can affect their compliance to treatment. There is a lot of interest in maintaining ovarian function after chemotherapy in order to ensure fertility and delay the symptoms of early menopause. The use of a gonadotropin-releasing hormone (GnRh) analogue, administered in combination with chemotherapy to protect ovarian reserve against cytotoxic damage, is one of the approaches that has been evaluated, although the rationale for its use is based mainly on hypothesis. Several phase ii studies have suggested a decreased incidence of amenorrhoea with the use of GnRh analogue concomitant with chemotherapy. however, the subsequent phase iii studies have produced conflicting results. in particular, the temporary ovarian suppression in combination with modern (neo)adjuvant chemotherapy for preventing premature menopause showed no benefit in three studies and an advantage in two studies. This use of a GnRh analogue is appealing but further randomised controlled trials are needed to evaluate its efficacy.
Many of these patients develop early menopause as a consequence of these treatments. Thus, infertility and premature menopause are relevant concerns for young women with cancer and may also influence their treatment compliance. 2 cancer treatments can temporarily or definitively damage the ovarian function, through the partial or total destruction of the ovarian reserve. chemotherapy may have a direct effect on primordial oocytes, causing apoptosis or indirectly damaging the granulosa cells and the ovarian stroma. [3] [4] [5] The probability of ovarian dysfunction after chemotherapy depends on the specific drugs used for the treatment, the dose, the schedule, the duration of the treatment, the age of the patient and her pre-treatment fertility status. The risk of permanent amenorrhoea is high with alkylating agents, intermediate with anthracyclines and taxanes and low with 5-fluorouracil and methotrexate. in particular, the combination regimen of oral cyclophosphamide, methotrexate and 5-fluorouracil (cMF) is associated with the highest risk of ovarian failure, which can reach a figure of 90 % in women older than 40. 6 Modern combination regimens with anthracyclines and taxanes have less ovarian toxicity, with 85 % of patients under 40 resuming menses within 1 year after chemotherapy. 7, 8 Women under 35 have a 10 % higher risk of premature menopause, a 50 % higher risk between 35 and 40, while women over 40 have an 85 % higher risk. 9 Young patients have a higher absolute number of primordial oocytes. Nonetheless, young patients face a sharp reduction of the ovarian reserve after toxic chemotherapy, and it has been demonstrated that menopause occurs earlier in cancer survivors. 10, 11 The use of tamoxifen at the end of chemotherapy contributes to delay the resumption of menses. Recent data support a longer duration of hormonal therapies for oestrogen receptor-positive breast cancer; 12, 13 therefore, larger numbers of women could be affected by the risk of compromised fertility. These women will be older and thus at higher risk for infertility at the time that their hormonal therapy is completed.
No ovarian toxicity has been reported even after prolonged use of trastuzumab. 14 it is well known that menstruation alone does not accurately reflect true ovarian function; measurement of anti-Mullerian hormone coupled with ultrasound-assisted antral follicle counting has been suggested as an effective mean of assessing the ovarian reserve following breast cancer chemotherapy.
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Interruption of Follicle-Stimulating Hormone Secretion alkylating agents may bring about an increased rate of destruction/ apoptosis of non-resting follicles, and subsequently a decrease in the secretion of sex steroids. the resultant decrease in their plasma concentrations and the negative feedback on the hypothalamus and pituitary gland cause an increase in follicle-stimulating hormone (FSH) secretion, with a great recruitment of preantral follicles to enter the oneway differentiational path of maturation. Since the follicles are further exposed to the gonadotoxic effect of chemotherapeutic agents, there is an increased, rapid depletion of the ovarian follicular reserve. this vicious cycle may be interrupted by the gnrH analogue administration through its ability to prevent the increase in FSH concentrations.
Decrease in Utero-ovarian Perfusion
High oestrogen concentrations significantly increase ovarian perfusion. the decrease in utero-ovarian perfusion, resulting from the hypo-oestrogenic state generated by gnrH analogue pituitary-gonadal desensitization, may result in a lower total cumulative exposure of the ovaries to chemotherapeutic agents and subsequently in less gonadotoxicity.
Activation of GnRH Receptors
It has been shown that primate and human gonads contain gnrH receptors. gnrH analogues could activate gnrH-I and gnrH-II receptors, resulting in decreased follicular apoptosis.
Up-regulation of Sphingosine-1-Phosphate
another possibility is that gnrH analogue may up-regulate an intragonadal antiapoptotic molecule such as sphingosine-1-phosphate.
It has been proved that this molecule is able to prevent oocyte death caused by doxorubicin and ionising radiations.
Protection of Undifferentiated Germ Line Stem Cells
In 2004, ground-breaking data were presented regarding the existence of germ line stem cells in the mouse ovary, which are able to regenerate the primordial follicle pool. one can hypothesise that the gnrH agonist protective effect possibly takes place through the protection of the undifferentiated stem cells, which ultimately generate de novo primordial follicles, thus replacing the ones destroyed by chemotherapeutic agents.
Clinical Use of GnRH Analogues
prevention of premature menopause and infertility are major concerns for young patients who are undergoing treatment for cancer. the possibility of administering a gnrH analogue to prevent chemotherapyinduced gonadal damage is attractive, although the data are derived only from studies in animal models. the first results arising from phase II studies have suggested a reduction of the incidence of amenorrhoea with the use of gnrH analogues during chemotherapy in young women.
However, the subsequent phase III studies conducted on premenopausal patients with early-stage breast cancer undergoing (neo)adjuvant chemotherapy, have produced conflicting data (see Table 1 ). the intention-to-treat analysis showed a rate of early menopause of 25.9% in the chemotherapy-alone group and 8.9 % in the chemotherapy plus triptorelin group. the number needed to treat was six. resumption of menses was observed in 49.6 % of patients in the chemotherapy-alone group versus 63.3 % of patients in the chemotherapy plus triptorelin group.
the median time to resumption of menstrual activity was 6.7 months in the patients treated with triptorelin and was not reached in the patients treated with chemotherapy alone. the resumption of menses was higher in hormone receptor-negative patients who did not receive tamoxifen; these data confirm that the administration of tamoxifen after chemotherapy is associated with an increased incidence of amenorrhoea. there were no differences in the incidence of disease recurrences or deaths in the two arms. 26 In addition to phase III studies, three meta-analyses have after chemotherapy, although there were no significant differences in pregnancy rates between the groups. the authors' conclusion was that gnrH analogues appear to be effective in protecting the ovaries during chemotherapy in terms of resumption of menses, but evidence for protection of long-term fertility is lacking. 27 In the second meta-analysis, data from eight randomised studies, involving 803 breast cancer and lymphoma patients randomly assigned to receive chemotherapy or chemotherapy and gnrH analogue, were collected. cancer that achieve amenorrhoea with adjuvant chemotherapy. However, available data seem to rule out the possible negative interference of gnrH analogues on the effectiveness of adjuvant chemotherapy. 30 Finally, a limitation to the use of gnrH analogue to preserve the ovarian function is the assumption that resumption of menses corresponds to retained fertility; these women may continue to menstruate after chemotherapy, despite having abnormal fertility. Since this has not been proved, other options should be considered, such as oocyte or embryo cryopreservation. these options are actually the only established fertilitypreservation methods: newer hormonal stimulation regimens (letrozole and tamoxifen) may be effective as traditional methods and their use may be preferred in women with hormone-sensitive cancer; letrozole, for instance, can enhance ovarian stimulation while keeping oestrogen levels near physiological levels.
Despite the attractiveness of the use of gnrH analogue in preventing ovarian failure for many advantages (simplicity in administration, no significant side effects, non-invasive method and the relatively low cost of the therapy), the question regarding its effectiveness, especially as method of fertility preservation, is still not resolved. given the current state of knowledge regarding these agents, the recent update of american Society of clinical oncology (aSco) clinical practice guidelines on fertility preservation for patients with cancer judged gnrH analogues, to date, as a not proved effective method of fertility preservation and stressed the need for a decisive study in which a larger number of more homogeneous patients will be randomised to a treatment with or without gnrH analogues, will be followed for a longer period of time and more sensitive ovarian reserve markers such as anti-mullerian hormone or antral follicle counts will be used.
